Martin Pölcher

TL;DR: This score is the first prospectively validated instrument to positively predict surgical outcome in recurrent ovarian cancer and will be enrolled in the recently started randomized prospective DESKTOP III trial investigating the role of surgery in recurrent platinum-sensitive ovarian cancer.

TL;DR: This multicentre, open-label, randomised, phase 3 trial was to compare a standard bevacizumab-containing regimen versus carboplatin-pegylated liposomal doxorubicin combined with bevacsumab for progression-free survival in recurrent ovarian cancer.

TL;DR: It is shown that targeted delivery of RIG-I agonists induced ovarian cancer cells to upregulate HLA class I and to secrete the proinflammatory cytokines CXCL10, CCL5, interleukin-6, tumor necrosis factor-alpha, and IFN-beta, which offer proof of principle that mimicking viral infection in ovarian cancer Cells triggers an immunogenic form of tumor cell apoptosis that may enhance immunotherapy of ovarian cancer.

TL;DR: MRI detects additional invasive carcinoma and proves to be a powerful supplement to the conventional work-up in the clinical management of breast cancer.

TL;DR: It is indicated that NAC elicited an immunologic profile in which low immunosuppressive Foxp3+ infiltration and elevated numbers of activated granzyme B+ cells were significantly associated with EOC-specific PFS, suggesting a contribution of immunologic effects to improved clinical outcome.